AstraZeneca is grappling with regulatory challenges as the Centers for Medicare & Medicaid Services seeks to dismiss its court challenge against a government drug price negotiation program. Despite mixed results from late-stage trials for a rare disease treatment, the company remains optimistic about achieving peak sales of $3 billion to $5 billion. Simultaneously, AstraZeneca has reported successful phase 3 trial results for its Imfinzi cancer treatment, which demonstrated significant improvements in patient survival rates, reinforcing the firm's potential in oncology.
“AstraZeneca Confident Rare-Disease Drug Can Hit Target After Mixed Study Results”
“Der britisch-schwedische Pharma-Gigant hat in den zurückliegenden Tagen mit gleich mehreren vielversprechenden Studiendaten in der späteren klinischen Entwicklungsphase aufhorchen lassen.”
“AstraZeneca said on Thursday that a combination treatment with its cancer drug Imfinzi showed significant improvement in how long patients with a common liver cancer lived before their disease worsened, in a late-stage trial.”
“AstraZeneca reported mixed results from three late-stage clinical trials of an experimental treatment for a rare metabolic disease, but remains confident the drug can generate annual peak sales of $3 billion to $5 billion.”
“AstraZeneca said on Thursday that a combination treatment with its cancer drug Imfinzi showed significant improvement in how long patients with a common liver cancer lived before their disease worsened, in a late-stage trial.”
“The Centers for Medicare & Medicaid Services is asking a federal court to dismiss AstraZeneca Plc’s challenge against a government drug price negotiation program, arguing a Biden-era law bars judicial review of the issue.”
“The company said the results support the drug’s potential to transform the treatment of hypophosphatasia and it plans to submit data to regulators as soon as possible.”
“O governo assinou acordo com AstraZeneca/Fiocruz em 31/07/2020 (base para compra e produção), com MP de R$ 1,9 bi em 06/08/2020.”
“o compromisso de compra da 1ª vacina (AstraZeneca) foi em 2020, bem antes da aprovação.”
“Yes, pharmaceutical companies like Pfizer, Johnson & Johnson, and AstraZeneca routinely partner with Harvard, Stanford, and Yale's medical/scientific labs for joint research, drug discovery, clinical trials, and data sharing.”
“Examples: - Yale-AstraZeneca Oncology Alliance (cancer research since 2017)”
“analysts call the overall hit limited (stocks dipped on initial jitters, not fundamentals).”
